ATE475671T1 - ANTIBODIES TO HUMAN NOGO A AND ITS PHARMACEUTICAL USE - Google Patents
ANTIBODIES TO HUMAN NOGO A AND ITS PHARMACEUTICAL USEInfo
- Publication number
- ATE475671T1 ATE475671T1 AT03782350T AT03782350T ATE475671T1 AT E475671 T1 ATE475671 T1 AT E475671T1 AT 03782350 T AT03782350 T AT 03782350T AT 03782350 T AT03782350 T AT 03782350T AT E475671 T1 ATE475671 T1 AT E475671T1
- Authority
- AT
- Austria
- Prior art keywords
- human
- antibodies
- binding molecule
- pharmaceutical use
- human nogo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0228832.2A GB0228832D0 (en) | 2002-12-10 | 2002-12-10 | Organic compound |
PCT/EP2003/013960 WO2004052932A2 (en) | 2002-12-10 | 2003-12-09 | Antibody (“11c7”) anti nogo a and its pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE475671T1 true ATE475671T1 (en) | 2010-08-15 |
Family
ID=9949456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03782350T ATE475671T1 (en) | 2002-12-10 | 2003-12-09 | ANTIBODIES TO HUMAN NOGO A AND ITS PHARMACEUTICAL USE |
Country Status (25)
Country | Link |
---|---|
US (2) | US7785593B2 (en) |
EP (1) | EP1572745B1 (en) |
JP (1) | JP4504200B2 (en) |
KR (1) | KR101215801B1 (en) |
CN (1) | CN100384877C (en) |
AT (1) | ATE475671T1 (en) |
AU (1) | AU2003289998B2 (en) |
BR (1) | BR0317161A (en) |
CA (1) | CA2509068C (en) |
CY (1) | CY1110848T1 (en) |
DE (1) | DE60333585D1 (en) |
DK (1) | DK1572745T3 (en) |
EC (1) | ECSP055849A (en) |
ES (1) | ES2349293T3 (en) |
GB (1) | GB0228832D0 (en) |
HK (1) | HK1084676A1 (en) |
IL (1) | IL169018A (en) |
MX (1) | MXPA05006265A (en) |
NO (1) | NO20053304L (en) |
PL (1) | PL210720B1 (en) |
PT (1) | PT1572745E (en) |
RU (1) | RU2350623C2 (en) |
SI (1) | SI1572745T1 (en) |
WO (1) | WO2004052932A2 (en) |
ZA (1) | ZA200504522B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
ATE440866T1 (en) * | 2003-12-22 | 2009-09-15 | Glaxo Group Ltd | NOGO-A-NEUTRALIZING IMMUNOLOBULINES FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
CA2614076A1 (en) * | 2005-07-05 | 2007-01-11 | Glaxo Group Limited | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
CA2704357C (en) * | 2007-11-02 | 2016-06-21 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use thereof |
EP2323691A2 (en) * | 2008-07-11 | 2011-05-25 | Glaxo Group Limited | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
WO2012004773A1 (en) | 2010-07-09 | 2012-01-12 | Universite De Geneve | New uses of nogo-a inhibitors and related methods |
EP2870177A1 (en) | 2012-07-05 | 2015-05-13 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
US20160135446A1 (en) * | 2013-06-13 | 2016-05-19 | Biomatrica, Inc. | Cell stabilization |
KR20180133399A (en) | 2016-03-01 | 2018-12-14 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | Antibodies specific for the human polyoviral receptor (PVR) |
JP2022553300A (en) | 2019-10-24 | 2022-12-22 | ノヴァゴー セラピューティクス アーゲー | Novel anti-Nogo-A antibody |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5180820A (en) | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
EP0531472B1 (en) * | 1991-03-06 | 2003-08-13 | MERCK PATENT GmbH | Humanized monoclonal antibodies |
EP2264174A3 (en) | 1998-07-22 | 2012-03-07 | SmithKline Beecham Limited | Protein similar to neuroendocrine-specific protein, and encoding CDNA |
SK287323B6 (en) | 1998-11-06 | 2010-07-07 | University Of Z�Rich | Nogo protein, its purified fragment, chimeric protein and purified molecule with its content, isolated nucleic acid, vector containing same, recombinant cell, method for producing recombinant protein and use thereof |
CU22921A1 (en) * | 1999-11-16 | 2004-02-20 | Centro Inmunologia Molecular | CHEMICAL, HUMANIZED ANTIBODIES AND THE SIMPLE CHAIN FV TYPE FRAGMENT RECOGNIZING ANTIGEN C2. ITS USE IN THE DIAGNOSIS AND TREATMENT OF COLORECTURAL TUMORS |
EP2163561A1 (en) | 2000-01-12 | 2010-03-17 | Yale University | NOGO receptor-mediated blockade of axonal growth |
EP1385545B1 (en) * | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
DE20110806U1 (en) | 2001-06-29 | 2001-12-20 | Jack Wolfskin Ausruestung Fuer | tent |
AR037456A1 (en) * | 2001-11-30 | 2004-11-10 | Biogen Inc | ANTIBODIES AGAINST MONOCITARY CHEMOTHOTAL PROTEINS |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
ATE440866T1 (en) * | 2003-12-22 | 2009-09-15 | Glaxo Group Ltd | NOGO-A-NEUTRALIZING IMMUNOLOBULINES FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
US7596225B2 (en) * | 2005-06-30 | 2009-09-29 | Alcatl-Lucent Usa Inc. | Method for refreshing a pairwise master key |
-
2002
- 2002-12-10 GB GBGB0228832.2A patent/GB0228832D0/en not_active Ceased
-
2003
- 2003-12-09 PL PL377506A patent/PL210720B1/en unknown
- 2003-12-09 CA CA2509068A patent/CA2509068C/en not_active Expired - Fee Related
- 2003-12-09 DK DK03782350.7T patent/DK1572745T3/en active
- 2003-12-09 CN CNB2003801096228A patent/CN100384877C/en not_active Expired - Fee Related
- 2003-12-09 SI SI200331887T patent/SI1572745T1/en unknown
- 2003-12-09 DE DE60333585T patent/DE60333585D1/en not_active Expired - Lifetime
- 2003-12-09 RU RU2005121669/13A patent/RU2350623C2/en not_active IP Right Cessation
- 2003-12-09 AU AU2003289998A patent/AU2003289998B2/en not_active Ceased
- 2003-12-09 ES ES03782350T patent/ES2349293T3/en not_active Expired - Lifetime
- 2003-12-09 EP EP03782350A patent/EP1572745B1/en not_active Expired - Lifetime
- 2003-12-09 WO PCT/EP2003/013960 patent/WO2004052932A2/en active Application Filing
- 2003-12-09 JP JP2004558049A patent/JP4504200B2/en not_active Expired - Fee Related
- 2003-12-09 AT AT03782350T patent/ATE475671T1/en active
- 2003-12-09 PT PT03782350T patent/PT1572745E/en unknown
- 2003-12-09 KR KR1020057010410A patent/KR101215801B1/en not_active IP Right Cessation
- 2003-12-09 US US10/538,201 patent/US7785593B2/en not_active Expired - Fee Related
- 2003-12-09 BR BR0317161-2A patent/BR0317161A/en active Search and Examination
- 2003-12-09 MX MXPA05006265A patent/MXPA05006265A/en active IP Right Grant
-
2005
- 2005-06-06 IL IL169018A patent/IL169018A/en not_active IP Right Cessation
- 2005-06-10 EC EC2005005849A patent/ECSP055849A/en unknown
- 2005-07-06 NO NO20053304A patent/NO20053304L/en not_active Application Discontinuation
-
2006
- 2006-02-08 ZA ZA200504522A patent/ZA200504522B/en unknown
- 2006-02-24 HK HK06102543.2A patent/HK1084676A1/en not_active IP Right Cessation
-
2010
- 2010-06-18 US US12/819,060 patent/US8535666B2/en not_active Expired - Fee Related
- 2010-10-19 CY CY20101100934T patent/CY1110848T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053304L (en) | NOGO A binding molecules and their pharmaceutical use | |
CY1119197T1 (en) | METHOD OF PROVIDING Disease-Specific Molecules and Targeting Objectives | |
CY1117387T1 (en) | Monoclonal N-11 Dispersed β-Amyloid Antibodies, COMPOSITIONS, METHODS AND USES | |
EA200801509A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7 | |
BRPI0607315A2 (en) | isolated polynucleotide, expression vector, composition, method of producing an antigen binding molecule, antigen binding molecule and the use thereof, method for detecting in vivo or in vitro the presence of egfr in a sample, engineered host cell , pharmaceutical composition and its use | |
ECSP056263A (en) | HUMANIZED ANTIBODIES RECOGNIZING THE BETA AMILOIDEO PEPTIDE | |
EA200901436A1 (en) | Antigen-binding proteins that bind PAR-2 | |
WO2006083964A3 (en) | Modified fusion molecules for treatment of allergic disease | |
CY1115014T1 (en) | Monoclonal Antibodies Specific For Ab1-42 With Therapeutic Properties | |
ATE440825T1 (en) | PYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | |
ATE492563T1 (en) | COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13 | |
DE602005026219D1 (en) | AGAINST THE MAMMALIAN EAG1 ION CHANNEL PROPER ANTIBODIES | |
ATE506072T1 (en) | IMMUNOGENIC AND CORRESPONDING ANTIBODIES SPECIFIC TO COMMON HIGH MOLECULAR AGGREGATION INTERMEDIATE PRODUCTS OF AMYLOIDS FROM PROTEINS OF DIFFERENT SEQUENCE | |
DE60130538D1 (en) | HUMANIZED ANTIBODIES TO CCR2 AND METHOD FOR THEIR USE | |
DE60032486D1 (en) | PRION PROTEIN PEPTIDES AND ITS USE | |
NO20061678L (en) | NOGO-A binding molecules and phytosocial applications thereof | |
DE602004016499D1 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY ENDURANCE | |
DE60228504D1 (en) | P53 BINDING T-CELL RECEPTOR MOLECULES AND THEIR USES | |
BRPI0407031A (en) | Compositions and methods for cancer treatment using igsf9 and liv-1 | |
WO2006029838A3 (en) | Secreted polypeptide species involved in alzheimer’s disease | |
Cai et al. | Identification of a cysteine-histidine thioether bridge bond in functional units d, e and f of β</inf> c<//inf>-haemocyanin of the gastropod Helix pomatia | |
TH71697A (en) | Molecules for the capture of NOGO-A and their use in medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1572745 Country of ref document: EP |